MetaVia (MTVA) shares were down 26% in recent Wednesday trading after the company reported positive results from its two-part phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated steatohepatitis, or MASH.

Part 1 of the trial is evaluating DA-1241, which is a novel g-protein-coupled receptor 119 agonist, against a placebo, while part 2 is examining the efficacy of combining DA-1241 with sitagliptin, a DPP-4 inhibitor.

The trial showed that DA-1241 resulted in a statistically significant reduction in alanine transaminase levels at weeks four and eight, with a near-significant reduction observed at week 16, the company said, adding that statistically significant results were also observed in several secondary endpoints, including reductions in controlled attenuation parameter and hemoglobin A1C.

The drug also demonstrated a strong safety profile, with mostly mild adverse events and no drug-related serious adverse events. MetaVia said that out of 109 randomized patients, 95 successfully completed the dosing.

Price: 1.65, Change: -0.58, Percent Change: -26.01